General Information

Model generation

The Alb-luciferase linearized fragment was microinjected into pronuclei of C57BL/6NCrl embryo.  Then the obtained transgenic positive mice were intraperitoneal (IP) injected with 0.15 mg/g D-luciferin (Perkin Elmer), dissolved in dH2O. At 10 min post-injection, mice were imaged using the IVIS Spectrum. The mouse from founder line 2 with specific fluorescence in the total liver region was selected as the founder mouse. Finally the Alb-luciferase transgenic mouse strain was established by mating the founder line 2 mice with wild C57BL/6NCrl mice.

Phenotypic information

1. Bioluminescence imaging in vivo

Fig1. Bioluminescence imaging in vivo of Alb-luciferase mice

Application field

1. In vivo tracing of mouse liver cells.

2. To study the regeneration of mouse liver cells. By detecting the fluorescence signal, the proliferation and regeneration capacity of liver cells can be observed, providing data support for the development of therapies to promote liver regeneration.

3. In gene therapy studies, C57BL/6-Alb-luciferase transgenic mice can be used to evaluate the effects of gene therapy methods on the liver. By detecting the fluorescence signal, the efficiency and safety of gene therapy can be determined.

Reference

1. Song XJ, Guo YS, Duo SJ, et al. A Mouse Model of Inducible Liver Injury Caused by Tet-On Regulated Urokinase  for  Studies  of  Hepatocyte  Transplantation.The  American  Journal  of Pathology. 2009, 175(5):1975-1983.